Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,166 across all filing types
Latest filing 2025-07-14 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Intimation of the Forty-Third Annual General Meeting of the Company and Record Date for payment of Dividend.
Regulatory Filings Classification · 95% confidence The document is an official communication from Lupin Limited to stock exchanges (NSE and BSE) regarding the scheduling of the Forty-Third Annual General Meeting (AGM) and the record date for payment of a final dividend for the financial year ended March 31, 2025. It mentions the date and time of the AGM, the dividend amount recommended by the Board, and the record date for dividend entitlement. The document does not contain the full AGM materials or presentations but is an intimation or announcement about the AGM and dividend record date. The document length is 2772 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly Notice of Dividend Amount (DIV). However, since it is about the intimation of the AGM and record date for dividend payment (not the dividend payment itself), it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about the AGM and dividend record date, not the actual dividend notice or voting results. Given the content and length, the best fit is Regulatory Filings (RNS).
2025-07-14 English
ESG Rating by NSE Sustainability Ratings & Analytics Limited.
Regulatory Filings Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about an ESG rating assigned independently by NSE Sustainability Ratings & Analytics Limited for FY24. The document is a brief announcement of ESG rating information and does not contain detailed ESG performance data or a full ESG report. It is not a full Environmental & Social Information report (SR), but rather a regulatory announcement related to ESG rating disclosure. Given the nature and length (1909 characters), it fits best under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-07-10 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges regarding the company's ESG rating assigned independently by NSE Sustainability Ratings & Analytics Limited for FY24. It is a regulatory disclosure pursuant to SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically Regulation 30, which mandates timely disclosure of material events. The document does not contain detailed ESG report data, financial statements, or management discussion, but simply informs about the ESG rating. The length is only 1909 characters, indicating it is a brief announcement rather than a full report. Therefore, it fits best under Environmental & Social Information (SR) as it relates to ESG rating disclosure, but since it is a brief regulatory announcement without detailed ESG report content, and given the regulatory context, it is more appropriate to classify it as a Regulatory Filing (RNS), which is the fallback for miscellaneous regulatory disclosures that do not fit other categories. Confidence is high due to clear regulatory reference and document content.
2025-07-10 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a confirmation certificate issued by MUFG Intime India Private Limited under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. It confirms the dematerialisation of securities for the quarter ended 30th June 2025, including acceptance/rejection of securities and updating the register of members. The document is short (2782 characters) and serves as a regulatory compliance confirmation rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or other report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for compliance confirmations and miscellaneous regulatory announcements that do not fit other specific categories.
2025-07-10 English
Certificate under Reg. 74(5) of SEBI (Depositories and Participant) Regulations, 2018, for the quarter ended on June 30, 2025.
Regulatory Filings Classification · 95% confidence The document is a confirmation certificate issued by MUFG Intime India Private Limited under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. It confirms the dematerialisation of securities for the quarter ended 30th June 2025, including acceptance/rejection of securities and updating the register of members. The document is short (2782 characters) and serves as a regulatory compliance confirmation rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for compliance confirmations and miscellaneous regulatory announcements that do not fit other specific categories.
2025-07-10 English
Lupin and Zentiva Sign License and Supply Agreement for Commercializing Certolizumab.
Regulatory Filings Classification · 95% confidence The document is a press release announcing a license and supply agreement between Lupin Limited and Zentiva for commercialization of a biosimilar product. It contains no financial statements, no regulatory filings, no voting results, no management changes, no earnings data, and no detailed financial or operational report. The document is a corporate announcement about a strategic partnership and commercial agreement. It is not a report, transcript, or regulatory filing. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-07-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.